nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).

被引：6
|
作者：
Firdaus, Irfan
Waterhouse, David Michael
Gutierrez, Martin
Wainberg, Zev A.
George, Ben
Kelly, Karen
Bekaii-Saab, Tanios S.
Carrizosa, Daniel R.
Soliman, Hatem Hussein
Fraser, Cindy Duval
Ko, Amy
Pierce, Daniel W.
Manax, Victoria G.
Stergiopoulos, Sotirios G.
Hochster, Howard S.
机构：
[1] Oncol Hematol Care Inc, Sarah Cannon Res Inst, Cincinnati, OH USA
[2] OHC Oncol Hematol Care, Blue Ash, OH USA
[3] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[4] Ronald Regan UCLA Med Ctr, Los Angeles, CA USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[8] Levine Canc Inst, Charlotte, NC USA
[9] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[10] Celgene Corp, Summit, NJ USA
[11] Celgene Corp, Great Neck, NY USA
[12] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps475
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS475
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 1B trial of ADI-PEG 20 (A) plus nab-Paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC).
    Lowery, Maeve Aine
    Capanu, Marinela
    Glassman, Danielle C.
    Covington, Christina M.
    Gluskin, Jill
    Brenner, Robin
    Li, Chien-Feng
    Bomalaski, John S.
    Johnston, Amanda
    Barba, Adalberto
    Yu, Kenneth H.
    Kelsen, David Paul
    Abou-Alfa, Ghassan K.
    Saltz, Leonard
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P plus GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Cranmer, Lee D.
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
  • [34] Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial
    Tehfe, Mustapha Ali
    Dowden, Scot D.
    Kennecke, Hagen F.
    El-Maraghi, Robert Hassan
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Penenberg, Darryl Neil
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [35] Activity, efficacy, and safety of nab-paclitaxel (Nab-P) and gemcitabine (G) in heavily pretreated advanced pancreatic cancer (APDAC) patients (pts): A multicenter retrospective analysis
    Febbraro, Antonio
    Zaniboni, Alberto
    Zagonel, Vittorina
    Di Costanzo, Francesco
    Malorino, Luigi
    Bertocchi, Paola
    Bergamo, Francesca
    Glommonl, Ellsa
    Giordano, Guida
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment
    Giordano, Guido
    Vaccaro, Vanja
    Lucchini, Eleonora
    Bertocchi, Paola
    Bergamo, Francesca
    Musettini, Gianna
    Santoni, Matteo
    Lo Re, Giovanni
    Giommoni, Elisa
    Russano, Marco
    Campidoglio, Serena
    Santini, Daniele
    Vasile, Enrico
    Cascinu, Stefano
    Zagonel, Vittorina
    Zaniboni, Alberto
    Melisi, Davide
    Milella, Michele
    Febbraro, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [37] Efficacy and safety of nab-Paclitaxel (nab-P) plus gemcitabine (Gem) vs gem alone in patients (Pts) with metastatic pancreatic cancer (MPC) treated to progressive disease (PD) in the phase III MPACT trial
    Vogel, A.
    Penenberg, D.
    McGovern, D.
    Romano, A.
    Michael, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S455 - S455
  • [38] The retrospective analysis of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Ueno, M.
    Kobayashi, S.
    Ohkawa, S.
    Tezuka, S.
    Moriya, S.
    Morimoto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 67 - 67
  • [39] Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study
    Yu, X.
    Shen, L.
    Hao, J.
    Wang, L.
    Pan, H.
    Han, G.
    Xu, J.
    Zhang, Y.
    Yang, S.
    Ying, J.
    Li, M.
    Begic, D.
    Lu, B.
    Xu, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 66 - 67
  • [40] nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial
    Philip, P. A.
    Lacy, J.
    Portales, F.
    Sobrero, A.
    Pazo-Cid, R.
    Manzano Mozo, J. L.
    Kim, E. S.
    Dowden, S.
    Zakari, A.
    Borg, C.
    Terrebonne, E.
    Rivera Herrero, F.
    Shiansong Li, J.
    Ong, T. J.
    Nydam, T.
    Hammel, P.
    ANNALS OF ONCOLOGY, 2017, 28
12345